• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics Inc (NQ: TVTX )

    17.66 +0.36 (+2.08%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Travere Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Travere Therapeutics Announces Pricing of Public Offering of Common Stock
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Announces Proposed Public Offering of Common Stock
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at Upcoming Investor Conferences
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    A Preview Of Travere Therapeutics's Earnings
    Via Benzinga
    Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
    Via Benzinga
    Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
    Via Benzinga
    Travere Therapeutics Reports Third Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
    Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
    Via Benzinga
    Travere Therapeutics to Report Third Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
    Via Benzinga
    Where Travere Therapeutics Stands With Analysts
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
    Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Ratings For Travere Therapeutics
    Via Benzinga
    TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
    The company could soon ask for approval of its only drug, Filspari, in a second disease. 
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
    Company to host conference call today at 4:30 p.m. ET 
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
    The company previously had an accelerated approval for its IgA nephropathy treatment. 
    Via Investor's Business Daily
    NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
    Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria 
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.